tirzepatide patent expiry date In weight loss battle, Novo and Lilly face growing offensive from licensed copies Tirzepatide | US Patents |

Clinical trial results In phase 3 trials, average weight loss over 68 weeks was: 20.4% with CagriSema 14.9% with semaglutide alone 11.5% with cagrilintide alone 3% with placebo Side effects were mostly mild to moderate, similar to current GLP-1s

Juul Holst and others spent decades researching and tweaking it so it could be used in medications

J Clin Endocrinol Metab (2015) 100(8):290917.10.1210/jc.2015-1176 32 MengJMaXWangNJiaMBiLWangYet alActivation of GLP-1 receptor promotes bone marrow stromal cell osteogenic differentiation through beta-catenin

This continuous support ensures that as you move through the dosing schedule, you are never left guessing about your next step

If your results need to be reproducible, the pen removes a whole class of human error